Etesevimab
Based on 1 Customer Validation
Etesevimab (JS016) is a recombinant neutralizing human IgG1 anti-SARS-CoV-2 monoclonal antibody.
For research use only. We do not sell to patients.
- Purity : 98.76%
- CAS No.: 2423948-94-9
- Molecular Weight:145.18 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Virus
IC50 & Target
Severe acute respiratory syndrome coronavirus 2
In Vitro
Etesevimab (JS016) binds the spike protein with a Kd of 6.45 nM and blocks spike protein attachment to the human angiotensin converting enzyme 2 (ACE2) receptor with an IC50 value of 0.32 nM (0.046 μg/mL)[1].
Etesevimab blocks viral cell fusion to prevent SARS-CoV-2 invasion of human cells and inhibits viral replication[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
43740600 [NCBI]
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 2423948-94-9
-
Appearance Liquid
-
Molecular Weight 145.18 kDa
-
Color Colorless to light yellow
-
SMILES
[Etesevimab]
-
Synonyms
CB 6; JS016
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Wu X, et al. Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study. Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0035021. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Etesevimab Related Classifications
HY-P99347 Related Classifications
Powered by Bioz